评估尼日利亚成人COVID-19疫苗(ChAd0x1、AD26.COV2.S和BNT162B2)分剂接种安全性和免疫原性的三盲随机对照试验:SIFCoVAN试验
这项多中心、非劣效性、三盲随机对照试验计划纳入1812名未接种过COVID-19疫苗的尼日利亚成人(18-65岁),随机分配至ChAd0x1、AD26.COV2.S和BNT162B2三种疫苗的不同剂量组,通过第28天抗SARS-CoV-2 S抗体血清转化(几何平均倍数升高≥2.5,非劣效界值20%)评估免疫原性,并评估安全性和不良事件。
要点
- 多中心、非劣效性、三盲随机对照试验,纳入1812名未接种过COVID-19疫苗的尼日利亚成人(18-65岁)。
- 主要免疫原性指标为第28天抗SARS-CoV-2 S抗体几何平均倍数升高≥2.5(非劣效界值20%),通过ELISA检测血清转化。
- 安全性通过接种后72小时内主动监测及第14天和第28天门诊访视评估。
核心结论
- 该试验将全面了解尼日利亚成人中COVID-19疫苗分剂接种与全剂量接种相比的免疫应答和安全性特征。
- 试验结果将指导政策实施,以在COVID-19大流行或未来流行病/大流行期间最大化有限疫苗的可及性。
研究设计与样本
- 多中心、非劣效性、三盲随机对照试验,纳入1812名未接种过COVID-19疫苗的参与者。
- ChAd0x1和AD26.COV2.S组各随机分配604名合格参与者,其中25%分剂组151名、50%分剂组151名、标准全剂量组300名。
- BNT162B2组随机分配604名参与者,其中50%分剂组201名、标准剂量组403名。
- 免疫原性通过基线和免疫后第28天采集血样,以ELISA检测抗SARS-CoV-2 S抗体,评估几何平均倍数升高≥2.5(非劣效界值20%)的血清转化。
- 安全性通过接种后72小时内主动评估及第14天和第28天门诊访视评估不良事件。
关键数值与推荐
- 主要免疫原性指标为抗SARS-CoV-2 S抗体几何平均倍数升高≥2.5,非劣效界值为20%。
- 次要免疫原性指标包括针对SARS-CoV-2变异株(α、δ和κ)的50%蚀斑减少中和试验及细胞因子产生(产生IFNα、γ和IL-2的CD4和CD8 T淋巴细胞)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The COVID-19 pandemic posed a major public health challenge with varying devastating effects on the global community. Vaccination is the most effective measure in combating this pandemic. A major challenge, especially in resource-limited settings, was the shortage of the vaccines. However, evidence by WHO in the use of fractionated doses in combating yellow fever prompted the evaluation of the safety and immunogenicity of fractionated doses of COVID-19 vaccines (ChAd0x1, AD26.COV2.S, and BNT162B2) among Nigerian adults (18-65 years). METHODS: This is a multi-center, non-inferiority randomized, triple-blind trial involving 1812 COVID-19 vaccine naïve participants. Six hundred four eligible participants will be randomized into each of the three vaccine arms of ChAd0x1, AD26.COV2.S, and BNT162B2 COVID-19 vaccine. 151 participants will be randomized each into the 25% and 50% fractionated dose and 300 in the standard full dose arm for the ChAd0x1 and AD26.COV2.S group. In the BNT162B2 group, 201 participants will be randomized into the 50% fractionated dose and 403 into the standard dose arms. The efficacy (immunogenicity) will be evaluated by collecting blood samples at baseline (day 0) and day 28 after immunization to determine the geometric mean fold rise (GMFR) of ≥ 2.5 within the range of 20% non-inferiority to the standard dose of anti-SARS-CoV-2 S antibody response detected by ELISA termed as seroconversion. Safety and adverse events will be evaluated through active evaluation during the first 72 h of vaccine administration and on days 14 and 28 of clinic visits. The trial will also assess secondary immunogenicity variables of 50% plaque plaalite reduction neutralization by antibodies against SARS-CoV-2 variants (α, δ, and κ) and cytokines production (IFNα, γ, and IL-2 producing CD4 and CD8 T lymphocytes). DISCUSSION: The proposed trial will allow for a comprehensive understanding of the immunologic responses and safety profile of fractional doses compared to full doses of COVID-19 vaccines among Nigerian adults. In addition, this will guide policy implementation for prompt vaccination of the population to maximize access to the limited vaccines available during the COVID-19 pandemic or future epidemics/pandemics. TRIAL REGISTRATION: The study is registered at the Pan African Clinical Trials Registry (PACTR), a primary registry in the WHO International Clinical Trial Platforms. PACTR202206754734018. Registered on June 1, 2022, Accessible at: https://pactr.samrc.ac.za/ Trial Sponsor: Open Philanthropy.
引用
- Musa AZ, Salako AO, Ayorinde JB, et al. A triple-blinded randomized control trial to evaluate the safety and immunogenicity of fractional doses of COVID-19 vaccines (ChAd0x1, AD26.COV2. S, and BNT162B2) among Nigeria adults: the SIFCoVAN trial. Trials. 2025. PMID: 41402886. doi:10.1186/s13063-025-09317-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。